Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:1790 |
Name | malignant mesothelioma |
Definition | A cell type cancer that has_material_basis_in mesothelial tissue that develops from the thin layer of tissue that covers many of the internal organs. |
Source | DiseaseOntology.org |
Alt Ids | DOID:6965 DOID:4487 DOID:7434 |
Path | disease disease of cellular proliferation cancer cell type cancer malignant mesothelioma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
Unknown unknown | Ad-NK4 | malignant mesothelioma | not applicable | detail... |
Unknown unknown | Avelumab | malignant mesothelioma | not applicable | detail... |
Unknown unknown | MGD013 | malignant mesothelioma | not applicable | detail... |
Unknown unknown | Pirfenidone | malignant mesothelioma | not applicable | detail... |
Unknown unknown | Pembrolizumab | malignant mesothelioma | not applicable | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01592383 | Phase II | Erlotinib | Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma | Completed | USA | 0 |
NCT01642342 | Phase I | sEphB4-HSA | Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors | Active, not recruiting | USA | 0 |
NCT02071862 | Phase I | Everolimus + Telaglenastat Erlotinib + Telaglenastat Docetaxel + Telaglenastat Telaglenastat Paclitaxel + Telaglenastat Cabozantinib + Telaglenastat | Study of the Glutaminase Inhibitor CB-839 in Solid Tumors | Completed | USA | 0 |
NCT02293005 | Phase II | Alisertib | Alisertib in Malignant Mesothelioma | Active, not recruiting | USA | 0 |
NCT02341625 | Phase Ib/II | BMS-986148 BMS-986148 + Nivolumab | A Study of BMS-986148 in Patients With Select Advanced Solid Tumors | Active, not recruiting | USA | CAN | 5 |
NCT02349958 | Phase II | Mitomycin C Cisplatin Doxorubicin | Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy | Recruiting | USA | 0 |
NCT02357147 | Phase II | Cisplatin + Pemetrexed Disodium Amatuximab | Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM). (ARTEMIS) | Terminated | USA | 5 |
NCT02372227 | Phase I | Defactinib + VS-5584 | A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma | Terminated | USA | 1 |
NCT02611024 | Phase Ib/II | Irinotecan + Lurbinectedin | Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors | Recruiting | USA | 1 |
NCT02628067 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Recruiting | USA | CAN | 19 |
NCT02628535 | Phase I | MGD009 | Safety Study of MGD009 in B7-H3-expressing Tumors | Terminated | USA | CAN | 1 |
NCT02760797 | Phase I | Emactuzumab + Selicrelumab | A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors | Completed | USA | 2 |
NCT02860286 | Phase II | Tazemetostat | Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma | Completed | USA | 2 |
NCT02963831 | Phase Ib/II | Durvalumab + ONCOS-102 | A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies | Recruiting | USA | 0 |
NCT03007030 | Phase II | Brentuximab vedotin | Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery | Recruiting | USA | 0 |
NCT03207347 | Phase II | Niraparib | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) | Recruiting | USA | 0 |
NCT03319537 | Phase Ib/II | MLN4924 Cisplatin + MLN4924 + Pemetrexed Disodium | Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma | Recruiting | USA | 0 |
NCT03477162 | Phase 0 | Metformin | Metformin Pharmacology in Human Cancers: A Proof of Principle Study | Recruiting | USA | 0 |
NCT03502746 | Phase II | Nivolumab + Ramucirumab | Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma | Recruiting | USA | 0 |
NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Recruiting | USA | 0 |
NCT03531840 | Phase II | Olaparib | Olaparib in People With Malignant Mesothelioma | Recruiting | USA | 0 |
NCT03538028 | Phase I | INCAGN02385 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | Completed | USA | 0 |
NCT03700294 | Phase I | ADCT-601 | Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors | Terminated | USA | 0 |
NCT03872206 | Phase Ib/II | HPN536 | Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression | Recruiting | USA | 0 |
NCT03936959 | Phase I | LY3434172 | A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer | Active, not recruiting | USA | 4 |
NCT04173338 | Phase I | Cabozantinib + Pemetrexed Disodium | Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma | Recruiting | USA | 0 |
NCT04515836 | Phase II | Olaparib | Olaparib in Patients With HRD Malignant Mesothelioma | Not yet recruiting | USA | 0 |